CLARITIN Drug Patent Profile

Which patents cover Claritin, and when can generic versions of Claritin launch?

Claritin is a drug marketed by Bayer Healthcare Llc and is included in eight NDAs.

The generic ingredient in CLARITIN is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin

A generic version of CLARITIN was approved as loratadine; pseudoephedrine sulfate by PERRIGO PHARMA INTL on January 30^th, 2003.

Summary for CLARITIN

US Patents:	0
Applicants:	1
NDAs:	8
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	118
Clinical Trials:	27
Patent Applications:	4,117
Drug Sales Revenues:	Drug sales revenues for CLARITIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CLARITIN
What excipients (inactive ingredients) are in CLARITIN?	CLARITIN excipients list
DailyMed Link:	CLARITIN at DailyMed

See drug sales revenues for CLARITIN

Recent Clinical Trials for CLARITIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andover Research Eye Institute	Phase 4
National Cancer Institute (NCI)	Early Phase 1
Rutgers, The State University of New Jersey	Early Phase 1

See all CLARITIN clinical trials

US Patents and Regulatory Information for CLARITIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN	loratadine	CAPSULE;ORAL	021952-001	Jun 16, 2008		OTC	Yes	Yes
Bayer Healthcare Llc	CLARITIN HIVES RELIEF REDITAB	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-003	Nov 19, 2003		OTC	Yes	Yes
Bayer Healthcare Llc	CLARITIN	loratadine	TABLET;ORAL	019658-002	Nov 27, 2002		OTC	Yes	Yes

Expired US Patents for CLARITIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN	loratadine	SYRUP;ORAL	020641-002	Nov 27, 2002	4,659,716*PED
Bayer Healthcare Llc	CLARITIN	loratadine	SYRUP;ORAL	020641-002	Nov 27, 2002	4,863,931*PED
Bayer Healthcare Llc	CLARITIN	loratadine	TABLET;ORAL	019658-002	Nov 27, 2002	4,863,931*PED

International Patents for CLARITIN

See the table below for patents covering CLARITIN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	638019
El Salvador	1999000068	JARABE ANTIHISTAMINICO ESTABILIZADO
Israel	63122	ANTIHISTAMINIC TRICYCLIC ALKYLCARBAMIC AND SULFAMIC ACID ESTERS,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Supplementary Protection Certificates for CLARITIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115

Market Dynamics and Financial Trajectory of Claritin (Loratadine)

Last updated: February 20, 2026

What Are the Key Market Drivers for Claritin?

Claritin (loratadine), an antihistamine used to treat hay fever and allergy symptoms, faces ongoing competition in an evolving pharmaceutical landscape. Its market position depends on patent status, regulatory approvals, and consumer preferences.

Patent and Regulatory Status

• The original patent for loratadine expired in the U.S. in 2002. Post-expiration, generic versions entered the market, reducing brand-specific revenue.
• The FDA approved Claritin, marketed by Bayer (now owned by Bayer AG), as a non-sedating antihistamine, gaining popularity in the late 1990s.
• Claritin's exclusivity period ended, but the brand maintained market share through marketing efforts and formulation distinctions.

Competition and Market Saturation

• Generic loratadine accounts for the majority of sales, with numerous brands available.
• Other second-generation antihistamines, such as cetirizine (Zyrtec) and fexofenadine (Allegra), have gained market share, impacting Claritin’s revenue.
• Over-the-counter (OTC) sales constitute a significant portion of total revenue, with increased availability boosting accessibility but intensifying competition.

Consumer Behavior and Healthcare Trends

• The aging population and increased allergy prevalence support sustained demand.
• Rising consumer preference for OTC medications reduces prescription-based sales but increases brand awareness.
• The trend toward natural remedies and alternative therapies may influence market growth.

How Has Claritin's Financial Trajectory Evolved?

Historical Revenue Patterns

Year	Estimated Global Sales (USD million)	Notes
2000	1,200	Before patent expiry
2002	850	Generic entry begins
2010	650	Market penetration of generics
2020	500	Decline due to competition
2022	470	Stabilization, OTC sales dominate

• Claritin's peak revenue occurred in the early 2000s before generic competition.
• Post-2002, sales declined sharply but stabilized through brand recognition and marketing.
• Recent figures suggest a plateau, with slight declines due to generic erosion.

Impact of Competition and Patent Expiry

• Patent expiration in 2002 triggered rapid sales decline.
• The introduction of generics, priced approximately 20-30% lower, led to increased market share of competitors.
• Bayer's strategy shifted toward maintaining brand presence through marketing and newer formulations.

Future Growth Prospects

• Diversification into combination formulations and new delivery methods (e.g., dissolvables).
• Expansion into emerging markets, where antihistamine demand is rising.
• Potential reformulations to address unmet needs such as longer duration or reduced side effects.

How Does Regulatory Policy Influence Claritin’s Markets?

• Regulatory agencies, including the FDA, allowed the proliferation of generics, eroding brand exclusivity.
• OTC switch in 2002 increased accessibility but diluted brand-specific revenues.
• Price regulation and healthcare policy shifts, like expanded OTC availability, impact overall sales.

Risks and Opportunities

Risks

• Patent cliffs for other formulations could compound generic competition.
• Market share erosion from newer antihistamines with better side-effect profiles.
• Regulatory changes limiting OTC marketing or sales.

Opportunities

• Growing allergy prevalence in developing countries.
• Innovations in delivery systems, such as extended-release formulations.
• Strategic acquisitions or licensing of novel antihistamines.

Key Financial Metrics and Market Share

Metric	2020	2022	Notes
Claritin Brand Revenue (USD million)	470	470	Stable, OTC-focused
Market Share (antihistamines)	15%	14%	Slight decline due to competition
Generic Loratadine Market Share	>60%	N/A	Dominant but lower revenue per unit

Conclusion

Claritin’s market is characterized by mature saturation, intense generic competition, and shifting consumer preferences toward OTC options. While revenue has stabilized at modest levels, growth opportunities exist in emerging markets, formulation innovation, and healthcare system adaptations. Strategic positioning and product innovation will be pivotal to maintaining relevance.

Key Takeaways

• Patent expiry in 2002 led to significant revenue decline, stabilized by brand loyalty.
• Generic competition now dominates, accounting for over 60% of loratadine sales.
• Claritin’s revenue remains among the top antihistamines due to strong marketing and OTC availability.
• Market growth favors emerging markets and new formulations; mature markets show limited upside.
• Regulatory environment favors OTC formulations, but price and generic erosion pressures persist.

FAQs

Q1: How significant is generic loratadine in the current market?
Generic loratadine accounts for the majority of total antihistamine sales, exceeding 60%, reducing Claritin’s market share and revenue.

Q2: What strategies can Claritin adopt to sustain market relevance?
Focusing on formulation improvements, expanding into emerging markets, and leveraging brand loyalty through advertising.

Q3: How does OTC availability affect Claritin’s revenue?
OTC status increases accessibility but intensifies competition from generics, leading to lower profit margins.

Q4: Which regions offer the most growth potential?
Emerging markets in Asia and Latin America, where allergy prevalence is rising and healthcare infrastructure is expanding.

Q5: What are the key risks for Claritin’s future?
Patent cliffs for future formulations, increasing competition from newer antihistamines, regulatory restrictions, and pricing pressures.

---

References

[1] IQVIA. (2022). Pharmaceutical Market Analysis.
[2] FDA. (2002). FDA Approval Letter for Claritin.
[3] Bayer AG. (2023). Annual Report.
[4] Statista. (2022). Over-the-counter (OTC) Drug Market Data.